all report title image
  • Published On : May 2023
  • Code : CMI5721
  • Industry : Pharmaceutical
  • Pages : 155
  • Formats :

The global Third Generation Sequencing market was valued at US$ 8.93 Bn in 2022 and is forecast to reach a value of US$ 23.92 Bn by 2030 at a CAGR of 13.1% between 2023 and 2030. The third-generation sequencing (TGS) market refers to the market for technologies and services related to third-generation sequencing platforms. These platforms offer advantages over traditional second-generation sequencing methods by providing longer read lengths, real-time sequencing capabilities, and the ability to directly sequence DNA or RNA molecules.

TGS technologies, such as Pacific Biosciences' Single Molecule Real-Time (SMRT) sequencing and Oxford Nanopore Technologies' nanopore sequencing, have gained significant attention in the field of genomics research, clinical diagnostics, and other applications. They enable researchers to obtain more comprehensive and accurate genomic information, which has implications for understanding genetic diseases, precision medicine, agricultural research, and environmental studies, among others.

Third Generation Sequencing Market Regional Insights

North America, particularly the United States, has been a leading market for TGS technologies, driven by significant investments in genomics research, advancements in healthcare, and the presence of major sequencing companies. Europe has also shown significant interest in TGS, with countries like the United Kingdom, Germany, and France being key players in the genomics and sequencing market.

Asia Pacific has emerged as a rapidly growing market for TGS technologies. Countries such as China, Japan, and South Korea have made substantial investments in genomics research and have a growing biotechnology industry. These factors contribute to the increasing adoption of TGS platforms and the development of regional market opportunities.

Third Generation Sequencing Market Drivers:

  1. Longer Read Lengths: TGS technologies offer significantly longer read lengths compared to traditional second-generation sequencing methods. This enables researchers to obtain more complete and accurate genomic information, including the ability to sequence long repetitive regions, structural variations, and complex genomes.
  2. Real-Time Sequencing: TGS platforms provide real-time sequencing capabilities, allowing researchers to monitor the sequencing process as it happens. This feature enables rapid data generation and analysis, facilitating applications such as infectious disease surveillance, monitoring of viral outbreaks, and time-sensitive clinical diagnostics.
  3. Direct Sequencing: TGS technologies have the ability to sequence DNA or RNA molecules directly, without the need for amplification or PCR (polymerase chain reaction). This reduces the risk of bias or errors introduced during amplification and streamlines the sequencing workflow, making it more efficient and cost-effective.
  4. Growing Demand for Precision Medicine: The field of precision medicine, which aims to tailor medical treatments to individual patients based on their genetic makeup, is driving the demand for comprehensive genomic information. TGS technologies play a crucial role in providing detailed genetic data that can be used to guide personalized treatment decisions.

Third Generation Sequencing Market Opportunities:

  1. Genomics Research: TGS technologies provide researchers with the ability to generate long-read sequences and capture complex genomic information. This opens up new opportunities for advancing genomics research, including the discovery of novel genetic variations, understanding gene regulation mechanisms, and studying the structure and function of genomes in greater detail.
  2. Clinical Diagnostics: TGS platforms offer potential applications in clinical diagnostics, especially in the identification and characterization of genetic variants associated with diseases. TGS can provide more comprehensive and accurate genetic information, enabling improved diagnosis, personalized treatment strategies, and monitoring of treatment response.
  3. Infectious Disease Surveillance: TGS platforms with real-time sequencing capabilities offer opportunities for rapid identification and characterization of infectious pathogens. This can aid in the surveillance and response to outbreaks, enabling timely intervention strategies and informed public health decisions.
  4. Agriculture and Crop Improvement: TGS technologies have applications in agriculture, allowing for the sequencing of plant and animal genomes with high accuracy and resolution. This can facilitate the identification of genetic variations associated with desirable traits, disease resistance, and yield improvement, leading to advancements in crop breeding and livestock management.

Third Generation Sequencing Market Trends:

  1. Technology Advancements: TGS technologies are continuously evolving, with ongoing advancements in sequencing chemistry, instrument performance, and data analysis tools. These advancements aim to improve accuracy, read lengths, sequencing speed, and cost-effectiveness of TGS platforms. Trends include the development of novel sequencing chemistries, miniaturization of sequencing devices, and improved base-calling algorithms.
  2. Increased Adoption of TGS Platforms: The adoption of TGS platforms has been steadily increasing across various industries and research fields. Researchers and healthcare professionals are recognizing the benefits of long-read sequencing and real-time sequencing capabilities offered by TGS technologies. As the technologies become more established and accessible, their adoption is expected to continue to grow.
  3. Expansion of Applications: TGS technologies are finding applications in an expanding range of fields beyond genomics research. This includes clinical diagnostics, precision medicine, agriculture, environmental studies, and more. The ability to generate long-read sequences and capture complex genomic information opens up new possibilities and drives the exploration of diverse applications.
  4. Integration with Existing Workflows: TGS platforms are increasingly being integrated into existing sequencing workflows and laboratory protocols. This includes complementing second-generation sequencing methods, leveraging the strengths of both technologies, and enabling comprehensive genomic analyses. Integrating TGS into established workflows improves efficiency and facilitates the adoption of TGS technologies in research and clinical settings.
CMI table icon

Third Generation Sequencing Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2022: US$ 8.93 Bn
Historical Data for: 2017 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 13.1% 2030 Value Projection: US$ 23.92 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Middle East and Africa: GCC Countries, Israel, Rest of Middle East, South Africa, North Africa, and Central Africa
Segments covered:
  • By Type of Technology: Single-molecule real-time (SMRT) sequencing, Nanopore sequencing, Others
  • By Product: Instruments, Reagents and consumables, Services
  • By Application: Genome sequencing, Epigenetics, Transcriptomics, Metagenomics, Others
  • By End User: Academic and research institutes, Pharmaceutical and biotechnology companies, Hospitals and clinics, Contract research organizations (CROs), Others
Companies covered:

Pacific Biosciences of California, Inc., Oxford Nanopore Technologies, Ltd., BGI Genomics Co., Ltd., F. Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., GenapSys Inc., Loop Genomics, Nabsys, Inc., Genia Technologies, Inc., Stratos Genomics, Inc., GATC Biotech AG, Phase Genomics, Inc.

Growth Drivers:
  • Longer Read Lengths
  • Real-Time Sequencing
  • Direct Sequencing
  • Growing Demand for Precision Medicine
Restraints & Challenges:
  • High Cost
  • Technical Challenges
  • Data Analysis Complexity

Third Generation Sequencing Market Restraints:

  1. High Cost: TGS technologies can be relatively expensive compared to traditional second-generation sequencing methods. The high cost of instruments, consumables, and data analysis can be a barrier to widespread adoption, particularly for smaller research institutions and clinical laboratories with limited budgets.
  2. Technical Challenges: TGS technologies face technical challenges that can limit their adoption and performance. These challenges include high error rates in sequencing reads, difficulties in sequencing highly repetitive regions, challenges in library preparation, and limited scalability for high-throughput applications. Overcoming these technical challenges is essential to further enhance the accuracy, reliability, and efficiency of TGS platforms.
  3. Data Analysis Complexity: TGS platforms generate large volumes of data with complex read structures, requiring advanced bioinformatics tools and computational resources for data analysis and interpretation. The complexity of TGS data analysis can be a barrier for researchers and healthcare professionals without specialized bioinformatics expertise, limiting the adoption and utilization of TGS technologies.

Recent Developments

New product launches

  1. Sequel II System by Pacific Biosciences (PacBio) - Released in 2019, Sequel II is an advanced TGS platform that offers higher throughput and improved read lengths compared to its predecessor, the PacBio Sequel system.
  2. GridION X5 by Oxford Nanopore Technologies - Introduced in 2019, GridION X5 is a scalable TGS platform that provides real-time nanopore sequencing. It offers flexible configurations to support various applications and throughput requirements.
  3. Ion Torrent Genexus System by Thermo Fisher Scientific - Introduced in 2019, the Genexus System combines semiconductor sequencing technology with an automated workflow. It offers an integrated solution for targeted sequencing and is aimed at clinical research and diagnostics.

Acquisition and partnerships

  1. Illumina's Acquisition of Pacific Biosciences (PacBio) - In 2018, Illumina announced its acquisition of Pacific Biosciences, a leading TGS technology provider. The acquisition aimed to combine Illumina's strengths in short-read sequencing with PacBio's long-read sequencing capabilities, offering researchers a comprehensive range of sequencing options.
  2. Roche's Acquisition of Genia Technologies - In 2014, Roche acquired Genia Technologies, a company focused on developing nanopore sequencing technologies. The acquisition aimed to leverage Genia's expertise in nanopore sequencing and further strengthen Roche's position in the TGS market.
  3. Oxford Nanopore Technologies' Partnerships - Oxford Nanopore Technologies has established several partnerships with academic institutions, research organizations, and companies to advance the field of TGS. These collaborations involve joint research projects, technology development, and applications across various fields, including genomics, infectious disease surveillance, and agriculture.

Top companies in Third Generation Sequencing Market

  1. Pacific Biosciences of California, Inc.
  2. Oxford Nanopore Technologies, Ltd.
  3. BGI Genomics Co., Ltd.
  4. F. Hoffmann-La Roche AG
  5. Illumina, Inc.
  6. Thermo Fisher Scientific Inc.
  7. QIAGEN N.V.
  8. Agilent Technologies, Inc.
  9. GenapSys Inc.
  10. Loop Genomics
  11. Nabsys, Inc.
  12. Genia Technologies, Inc.
  13. Stratos Genomics, Inc.
  14. GATC Biotech AG
  15. Phase Genomics, Inc.

Third-generation sequencing (also known as long-read sequencing) is a class of DNA sequencing methods. Third-generation sequencing works by reading nucleotide sequences at a single molecule level, which is capable of producing substantially much longer reads than the current methods. It has the ability to generate longer reads than second-generation sequencing, also known as next-generation sequencing. Moreover, third-generation sequencing has emerged as the ‘gold-standard’ technology for cDNA sequencing.

Market Dynamics:

Rising prevalence of chronic and infectious diseases, increasing applications in clinical diagnosis, growing applications of genomics, rise in focus on drug discovery and development, and growing efficiency compared to traditional technologies are major factors expected to propel growth of the global third generation sequencing market.

For instance, with the rise in burden of chronic disease, the usage or demand for third-generation sequencing technology-based devices is also increasing with a rapid pace. According to the World Health Organization (WHO), September 2022 report, non-communicable diseases (NCDs) kill 41 million individuals each year, equivalent to 74% of all deaths worldwide. Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).

Moreover, according to the Centers for Disease Control and Prevention (CDC), chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the U.S.

Key features of the study:

  • This report provides in-depth analysis of the global third generation sequencing market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global third generation sequencing market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Phase Genomics, Inc., GenapSys Inc., GATC Biotech AG, Stratos Genomics, Inc., Genia Technologies, Inc., Nabsys, Inc., Loop Genomics, Agilent Technologies, Inc., QIAGEN N.V., Illumina, Inc., F. Hoffmann-La Roche AG, BGI Genomics Co., Ltd., Oxford Nanopore Technologies, Ltd., Thermo Fisher Scientific Inc., and Pacific Biosciences of California, Inc., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global third generation sequencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global third generation sequencing market.

Detailed Segmentation:

  • Global Third Generation Sequencing Market, By Technology:
    • Single-Molecule Real-Time (SMRT) Sequencing
    • Nanopore Sequencing
    • Others
  • Global Third Generation Sequencing Market, By Product:
    • Instruments
    • Reagents and Consumables
    • Services
  • Global Third Generation Sequencing Market, By Application:
    • Genome Sequencing
    • Epigenetics
    • Transcriptomics
    • Metagenomics
    • Others
  • Global Third Generation Sequencing Market, By End user:
    • Academic and Research Institutes
    • Pharmaceutical and Biotechnology Companies
    • Hospitals and Clinics
    • Contract Research Organizations (CROs)
    • Others
  • Global Third Generation Sequencing Market, By Geography:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles:
    • Phase Genomics, Inc.
    • GATC Biotech AG
    • Stratos Genomics, Inc.
    • Genia Technologies, Inc.
    • Nabsys, Inc.
    • Loop Genomics
    • GenapSys Inc.
    • Agilent Technologies, Inc.
    • QIAGEN N.V.
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche AG
    • BGI Genomics Co., Ltd.
    • Oxford Nanopore Technologies, Ltd.
    • Pacific Biosciences of California, Inc.

Frequently Asked Questions

The global third generation sequencing market size was valued at US$ 8.93 Bn in 2022 and is expected to reach US$ 23.92 Bn by 2030.
The major factors driving the market are longer read lengths, real-time sequencing capabilities, direct sequencing without amplification, and the increasing demand for precision medicine.
North America is the prominent region in the market.
The market growing at a CAGR of 13.1% during the forecast period.
Pacific Biosciences of California, Inc., Oxford Nanopore Technologies, Ltd., BGI Genomics Co., Ltd., F. Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., GenapSys Inc., Loop Genomics, Nabsys, Inc., Genia Technologies, Inc., Stratos Genomics, Inc., GATC Biotech AG, Phase Genomics, Inc.

Related Reports


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo